<?xml version="1.0" encoding="UTF-8"?><shares><share isin="JE00B2QKY057" symbol="SHP" industry="Biotechnology" sector="Healthcare" name="Shire ltd" address="Hampshire International Business Park, Chineham, Basingstoke, RG24 8EP, UK" website="www.shire.com" summary="Shire Ltd., formerly Shire plc, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. In June 2007, the Company received an approvable letter from the United States Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a non-stimulant selective alpha-2A-receptor agonist. On November 7, 2007, Shire entered into a license agreement with Amicus Therapeutics, Inc. (Amicus), under which it received the rights to three compounds, PLICERA, AMIGAL and AT2220, in markets outside the United States. In April 2008, Shire announced the acquisition of arylsulfatase-A (ASA), an enzyme replacement therapy (ERT) in Phase I-II clinical trials for metachromatic leukodystrophy (MLD) from the Danish company, Zymenex A/S."></share></shares>
Submit an article or tip